FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>
SIAILMENT	OI CITAINOLS	IN DENEL IOIAL	CAMINETON

l	OIVIB APPROVAL								
l	OMB Number:	3235-0287							
l	Estimated average burde	n							
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Marucci Anthony S				2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [ CLDX ]								(Ch	elationship o eck all applica Director	able)	g Perso	on(s) to Issue 10% Ow Other (sp	ner	
(Last) (First) (Middle) C/O CELLDEX THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 08/05/2011								below)	below) President & CEO					
119 FOURTH AVENUE				4	If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street) NEEDHA		IA citate)	02494 (Zip)	_									Line	X Form fil	,	•	rting Person One Reporti	ng
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				e	Execution Date		e, 1 (ar) 8	3. Transacti Code (Ins 8) Code V	on str.	(A) or		tr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form:	Direct Indirect B	. Nature of ndirect eneficial wnership nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, Truity or Exercise (Month/Day/Year) if any		Code	nsaction de (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date of Se (Month/Day/Year) Unde Deriv			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership of Form: E Direct (D) C	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exer	e rcisable		kpiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Incentive Stock Option	\$2.8	08/05/2011		A		180,400		08/0	)5/2012 <sup>(1)</sup>	08	3/05/2021	Common Stock	180,400	\$2.8	180,40	00	D	

## **Explanation of Responses:**

1. 25% vest on August 5, 2012 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Anthony S. Marucci 08/08/2011

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.